Home / Market News / $REGN
benzinga Corporate Catalyst Impact 55/100 ● positive

RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $810

Oct 8, 2026, 2:09 PM UTC · Primary ticker $REGN

RBC Capital analyst Brian Abrahams reiterated a 'Sector Perform' rating on Regeneron Pharmaceuticals and increased its price target from $737 to $810. This indicates a moderately positive outlook from the analyst, suggesting potential upside for the stock based on their updated valuation.

RBC Capital's analyst Brian Abrahams maintained a 'Sector Perform' rating on Regeneron Pharmaceuticals while raising the price target from $737 to $810. This action signals a continued, albeit not overwhelmingly bullish, confidence in the company's prospects and an updated valuation that suggests more upside than previously anticipated. This primarily affects Regeneron shareholders and potential investors, as it provides an updated professional assessment of the stock's value. In the short term, this could lead to a modest positive reaction in REGN's stock price as investors react to the higher price target. Long-term implications depend on whether the company's performance aligns with or exceeds this revised analyst expectation. A key opportunity for traders is to consider this updated valuation in their investment decisions, although the 'Sector Perform' rating suggests the analyst doesn't see it as a strong outperform candidate.

$REGN positive Analyst price target increase
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.